(Q35543387)

8 August 2017

1 reference

title

Impact of the new National Cholesterol Education Program (NCEP) guidelines on patient management (English)

1 reference

8 August 2017

Impact of the New National Cholesterol Education Program (NCEP) Guidelines on Patient Management (English)

1 reference

https://api.crossref.org/works/10.1111/J.1745-7599.2003.TB00408.X

continuing nursing education

14 March 2024

main subject

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14509100

14 March 2024

author name string

Anne Peters Harmel

1

1 reference

8 August 2017

Kathy Berra

2

1 reference

8 August 2017

language of work or name

1 reference

1 August 2003

1 reference

full work available at URL

8 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1745-7599.2003.tb00408.x

1 reference

https://api.crossref.org/works/10.1111/J.1745-7599.2003.TB00408.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1745-7599.2003.tb00408.x

14 March 2024

1 reference

https://api.crossref.org/works/10.1111/J.1745-7599.2003.TB00408.X

Journal of the American Academy of Nurse Practitioners

14 March 2024

published in

1 reference

8 August 2017

volume

15

1 reference

8 August 2017

issue

8

1 reference

8 August 2017

page(s)

350-360

1 reference

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB00408.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB00408.X

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB00408.X

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB00408.X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB00408.X

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB00408.X

Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB00408.X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7599.2003.TB00408.X

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1111/J.1745-7599.2003.TB00408.X

Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)

14 March 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1745-7599.2003.TB00408.X

14 March 2024

Identifiers

1 reference

8 August 2017

1 reference